The short version of Drug affinity complex fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-16. Anything still debated is marked as such rather than presented as settled.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Analysis of CRISPR sequences revealed coevolution of host and viral genomes. The basic model of CRISPR evolution is newly incorporated spacers driving phages to mutate their genomes to avoid the bacterial immune response, creating diversity in both the phage and host populations. To resist a phage infection, the sequence of the CRISPR spacer must correspond perfectly to the sequence of the target phage gene. Phages can continue to infect their hosts' given point mutations in the spacer. Similar stringency is required in PAM or the bacterial strain remains phage sensitive.
== Decay == Thorium-232 has a half-life of 14 billion years; it is itself an essentially pure alpha emitter with its first decay product radium-228. Radium-228 is itself unstable and leads to a decay chain known as the thorium series, which terminates at stable lead-208. The intermediates in the thorium-232 decay chain are all relatively short-lived; the longest-lived intermediate decay products are radium-228 and thorium-228, with half-lives of 5.75 years and 1.91 years, respectively. All others have half-lives under four days. The main decay branches are shown below:
== Other animals == Most mammals normally cease to produce lactase and become lactose intolerant after weaning. The downregulation of lactase expression in mice could be attributed to the accumulation of DNA methylation in the Lct gene and the adjacent Mcm6 gene.
=== Blockade of payment systems === In June 2026, the United States warned about the blockade of payment systems, including Visa and Mastercard with a goal of limiting tourism on the island, from which the Cuban government uses as a source of income.
Sources: en.wikipedia.org
at the top. Each layer of fluid moves faster than the one just below it, and friction between them gives rise to a force resisting their relative motion. In particular, the fluid applies on the top plate a force in the direction opposite to its motion, and an equal but opposite force on the bottom plate. An external force is therefore required in order to keep the top plate moving at constant speed. In many fluids, the flow velocity is observed to vary linearly from zero at the bottom to
== Biosynthesis == At least two enzyme families convert L-amino acids to D-amino acids. Amino-acid racemase, a PLP-dependent enzyme, racemizes amino acids via the formation of the α-iminoacids, where the stereogenic center is lost. L-amino-acid oxidases convert L-amino acids to the α-ketoacids, which are susceptible to reductive amination. Some amino acids are prone to racemization, one example being lysine, which racemizes via formation of pipecolic acid. In peptides, L-amino acid residues slowly racemize, resulting in the formation of some D-amino acid residues. Racemization occurs via deprotonation of the methyne that is alpha to the amido group. Rates increase with pH. Many D-amino acids found in higher organisms are derived from microbial sources. The D-alanine in peptidoglycans that comprise bacterial cell walls helps its host resist attack by proteolytic enzymes. Several antibiotics, e.g. bacitracin, contain D-amino acid residues.
Iraq's government made no secret that it would attack Israel if invaded. Prior to the war's start, in the aftermath of the failed US–Iraq peace talks in Geneva, Switzerland, a reporter asked Iraq's English-speaking foreign minister and deputy prime minister Tariq Aziz: "Mr. Foreign Minister, if war starts ... will you attack Israel?" His response was: "Yes, absolutely, yes." Five hours after the first attacks, Iraq's state radio broadcast declared that "The dawn of victory nears as this great showdown begins." Iraq fired eight missiles the next day. These missile attacks were to continue throughout the war. Iraq fired 88 Scud missiles during the war's seven weeks. Iraq hoped to provoke a military response from Israel. The Iraqi government hoped that many Arab states would withdraw from the Coalition, as they would be reluctant to fight alongside Israel. Following the first attacks, Israeli Air Force jets were deployed to patrol the northern airspace with Iraq. Israel prepared to militarily retaliate, as its policy for the previous 40 years had always been retaliation. However, President Bush pressured Israeli prime minister Yitzhak Shamir not to retaliate and withdraw Israeli jets, fearing that if Israel attacked Iraq, the other Arab states would either desert the coalition or join Iraq. It was also feared that if Israel used Syrian or Jordanian airspace to attack Iraq, they would intervene in the war on Iraq's side or attack Israel. The coalition promised to deploy Patriot missiles to defend Israel if it refrained from responding to the Scud attacks.
=== Possible future treatments === A peptide that prevents and treats citrus greening disease in greenhouse trials was being tested in field trials in 2021; an enhanced injectable version of the product was being developed in 2020. Two types of antisense oligonucleotide (FANA and Morpholinos) can be delivered efficiently into citrus trees, suppressing their RNA targets. FANA can suppress 'Candidatus Liberibacter asiaticus' in citrus trees. Morpholinos can suppress CLas in infected citrus trees and the psyllid vectors. Furthermore, the PPMOs designed to endosymbiotic bacteria of the psyllid vectors, can reduce psyllid populations by targeting and suppressing the insects endosymbionts, the bacteria which are essential for psyllid survival. Morpholinos must be covalently linked with a charged molecule or peptide, to enter bacteria. The target RNA is made susceptible to cleavage by ribonuclease P (RNase-P). Researchers at the Chinese Academy of Sciences found that the E3 ubiquitin ligase PUB21 acts as an essential susceptibility gene, marking the MYC2 transcription factor for degradation. Introduction of a dominant negative variant of PUB21 was successful in conferring resistance to HLB by stabilizing MYC2 levels.
=== Examples of intraarticular fractures === Bennett's Fracture intraarticular fracture of the base of the first metacarpal Rolando Fracture comminuted intraarticular fracture of the base of the first metacarpal Calcaneal Fracture fracture of the calcaneus that may extend into the subtalar joint Tibial Plateau Fracture fracture of the proximal portion of the tibia that may extend into the knee joint Pilon Fracture fracture of the distal articular surface of the tibia Distal Radius Fracture fracture of the distal portion of the radius that may extend into the wrist joint Olecranon Fracture fracture of the olecranon process of the ulna at the elbow Femoral Head Fracture fracture of the head of the femur that may extend into the hip joint Some of these fractures such as a Bennett's or Rolando fracture are coined based on their intraarticular involvement, while others such as femoral head fractures, tibial plateau fractures, and distal radius fractures may or may not extend into the joint.
Sources: en.wikipedia.org
Samir Mitragotri (born 28 May 1971) is an Indian American professor at Harvard University, an inventor, an entrepreneur, and a researcher in the fields of drug delivery and biomaterials. He is currently the Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences and the Wyss Institute for Biologically Inspired Engineering. Prior to 2017, he was the Duncan and Suzanne Mellichamp Chair Professor at University of California, Santa Barbara.
==== Combined malonic and methylmalonic aciduria (CMAMMA) ==== In the metabolic disease combined malonic and methylmalonic aciduria (CMAMMA) due to ACSF3 deficiency, there is an altered composition of complex lipids as a result of impaired mitochondrial fatty acid synthesis (mtFAS), so for example the content of cardiolipins is strongly increased.
=== Second stranding === Between January 9 and January 15, a storm tide dragged the carcass out to sea, but it washed ashore again on the next tide, on Crescent Beach, two miles to the south of its original location. Webb sent photographs of the mass, along with a description, to Joel Asaph Allen of the Museum of Comparative Zoology at Harvard. Allen apparently did not respond, but Webb's letter came to the attention of Prof. Addison Emery Verrill of Yale, at that time the foremost authority on cephalopods in the country. At first, Verrill suggested the carcass might represent the remains of a giant squid. In the January 1897 issue of the American Journal of Science he wrote:
== Further reading == García-Colín, L.S.; Velasco, R.M.; Uribe, F.J. (August 2008). "Beyond the Navier–Stokes equations: Burnett hydrodynamics". Physics Reports. 465 (4): 149–189. Bibcode:2008PhR...465..149G. doi:10.1016/j.physrep.2008.04.010.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.